Clinical Trial Update: Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a combination of ibrutinib, obinutuzumab, and venetoclax in patients with B-cell chronic lymphocytic leukemia, including relapsed dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• B-cell Chronic Lymphocytic Leukemia in Relapse
• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Grupo Cooperativo de Hemopatías Malignas | Conditions: B-Cell Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis) | Phase 2 | Status: COMPLETED